Security Snapshot

BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) Institutional Ownership

CUSIP: 10806X102

13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

427

Shares (Excl. Options)

188,213,795

Price

$76.49

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
BBIO on Nasdaq
Shares outstanding
201,803,957
Price per share
$74.26
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
188,213,795
Total reported value
$14,404,255,681
% of total 13F portfolios
0.02%
Share change
+653,090
Value change
+$187,214,916
Number of holders
427
Price from insider filings
$74.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 10806X102.
  • 427 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 427 to 36 between Q4 2025 and Q1 2026.
  • Reported value moved from $14,404,255,681 to $27,215,601.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 427 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 10806X102?
CUSIP 10806X102 identifies BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KKR Genetic Disorder L.P. 7% -31% $476,864,517 -$215,760,000 13,260,971 -31% KKR Genetic Disorder L.P. 12 May 2025
VIKING GLOBAL INVESTORS LP 6.1% -10% $880,129,695 -$87,989,901 11,842,434 -9.1% VIKING GLOBAL INVESTORS LP 31 Mar 2026
JANUS HENDERSON GROUP PLC 5.7% $845,275,116 11,000,457 JANUS HENDERSON GROUP PLC 31 Dec 2025
Kumar Neil 4.6% -16% $689,354,243 -$87,903,790 9,282,982 -11% NEIL KUMAR 31 Mar 2026

As of 31 Dec 2025, 427 institutional investors reported holding 188,213,795 shares of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO). This represents 93% of the company’s total 201,803,957 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.4% 16,862,691 +0.18% 0.02% $1,289,827,235
BlackRock, Inc. 7.2% 14,549,529 +0.96% 0.02% $1,112,893,458
VIKING GLOBAL INVESTORS LP 7.1% 14,393,934 -9.9% 2.9% $1,100,992,012
Kohlberg Kravis Roberts & Co. L.P. 6.6% 13,260,971 0% 16% $1,014,331,672
JANUS HENDERSON GROUP PLC 5.5% 11,000,457 +26% 0.38% $841,348,639
FARALLON CAPITAL MANAGEMENT LLC 4.5% 8,998,463 +9.8% 4% $688,292,435
Aisling Capital Management LP 2.5% 5,089,611 -16% 81% $389,304,345
STATE STREET CORP 2.5% 4,962,866 -11% 0.01% $379,609,620
Invesco Ltd. 2.4% 4,831,305 +23% 0.06% $369,546,521
GEODE CAPITAL MANAGEMENT, LLC 2.2% 4,412,523 +13% 0.02% $344,688,555
PRICE T ROWE ASSOCIATES INC /MD/ 1.9% 3,828,746 +144% 0.03% $292,862,000
Frazier Life Sciences Management, L.P. 1.8% 3,545,557 -7.8% 7.3% $271,199,655
FMR LLC 1.2% 2,390,362 +41% 0.01% $182,838,766
WELLINGTON MANAGEMENT GROUP LLP 1.2% 2,348,731 +130% 0.03% $179,654,434
D. E. Shaw & Co., Inc. 1.1% 2,214,031 -1.7% 0.13% $169,351,231
FRANKLIN RESOURCES INC 1.1% 2,164,928 +50% 0.04% $165,595,356
ALLIANCEBERNSTEIN L.P. 1% 2,050,746 -12% 0.05% $156,861,562
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.98% 1,975,315 +3.2% 0.12% $151,011,883
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.97% 1,964,419 +2% 0.02% $150,258,409
TWO SIGMA INVESTMENTS, LP 0.96% 1,947,047 -16% 0.22% $148,929,625
Capital Research Global Investors 0.96% 1,934,698 +0.08% 0.03% $147,985,050
UBS Group AG 0.93% 1,875,665 -27% 0.03% $143,469,616
SC US (TTGP), LTD. 0.92% 1,860,364 0% 1% $142,299,242
GOLDMAN SACHS GROUP INC 0.88% 1,782,833 -19% 0.02% $136,368,897
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.85% 1,725,266 0% 0.2% $131,966,000

Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 366,557 $27,215,601 +$6,993,895 $74.26 36
2025 Q4 188,213,795 $14,404,255,681 +$187,214,916 $76.49 427
2025 Q3 184,963,434 $9,606,937,258 -$158,160,333 $51.94 389
2025 Q2 188,818,044 $8,154,464,813 +$171,957,099 $43.18 357
2025 Q1 185,173,982 $6,405,659,483 +$325,204,372 $34.57 302
2024 Q4 176,645,317 $4,847,193,349 +$87,655,048 $27.44 260
2024 Q3 172,596,886 $4,393,814,683 -$68,086,150 $25.46 251
2024 Q2 174,953,530 $4,431,556,073 +$57,307,408 $25.33 249
2024 Q1 171,539,419 $5,303,582,949 +$162,256,099 $30.92 240
2023 Q4 165,715,337 $6,690,573,516 +$142,779,397 $40.37 246
2023 Q3 161,102,840 $4,243,730,776 +$304,390,990 $26.37 219
2023 Q2 149,815,028 $2,576,329,186 -$39,862,601 $17.20 196
2023 Q1 152,372,388 $2,526,139,807 +$155,256,748 $16.58 210
2022 Q4 144,623,389 $1,101,997,850 -$14,634,842 $7.62 175
2022 Q3 145,248,661 $1,443,911,522 +$48,733,339 $9.94 170
2022 Q2 140,449,294 $1,275,283,327 -$23,547,672 $9.08 153
2022 Q1 143,303,557 $1,454,787,082 -$23,988,513 $10.15 167
2021 Q4 141,976,495 $2,367,117,577 -$117,448,257 $16.68 181
2021 Q3 140,028,398 $6,563,888,337 -$165,004,819 $46.87 206
2021 Q2 142,676,491 $8,697,122,835 +$97,636,690 $60.96 197
2021 Q1 141,085,070 $8,688,930,801 +$1,238,074,220 $61.60 194
2020 Q4 121,079,579 $8,609,553,572 +$172,667,185 $71.11 160
2020 Q3 117,841,767 $4,393,419,330 +$21,644,575 $37.52 128
2020 Q2 117,300,177 $3,824,660,106 +$145,729,688 $32.61 114
2020 Q1 112,894,365 $3,273,779,385 +$162,480,179 $29.00 93
2019 Q4 100,520,271 $3,523,336,508 +$149,163,509 $35.05 85
2019 Q3 103,303,295 $2,217,864,724 +$112,320,073 $21.47 75
2019 Q2 99,927,998 $2,695,534,750 +$2,695,534,740 $26.97 60